- Home
- TVTX vs GNTX Comparison
TVTX vs GNTX Comparison
Compare TVTX & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TVTX | GNTX |
|---|---|---|
| Founded | N/A | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.0B |
| IPO Year | 2013 | 1995 |
Fundamental Metrics
Financial Performance| Metric | TVTX | GNTX |
|---|---|---|
| Price | $59.10 | $22.42 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 5 |
| Target Price | ★ $40.62 | $26.60 |
| AVG Volume (30 Days) | 1.4M | ★ 2.0M |
| Earning Date | 05-04-2026 | 04-24-2026 |
| Dividend Yield | N/A | ★ 2.10% |
| EPS Growth | ★ 92.89 | N/A |
| EPS | N/A | ★ 1.00 |
| Revenue | N/A | ★ $2,534,268,965.00 |
| Revenue This Year | $44.76 | $6.89 |
| Revenue Next Year | $35.51 | $4.58 |
| P/E Ratio | ★ N/A | $22.04 |
| Revenue Growth | N/A | ★ 9.55 |
| 52 Week Low | $22.06 | $20.48 |
| 52 Week High | $68.73 | $29.01 |
Technical Indicators
Market Signals| Indicator | TVTX | GNTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.84 | 45.14 |
| Support Level | $53.76 | $22.28 |
| Resistance Level | $59.93 | $24.99 |
| Average True Range (ATR) | 2.57 | 0.38 |
| MACD | -0.91 | 0.01 |
| Stochastic Oscillator | 10.09 | 43.54 |
Price Performance
Historical ComparisonAbout TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
About GNTX Gentex Corporation
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion, with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.